AS EARLY AS
DAY 2
RAPID
IMPROVEMENT
IN NASAL CONGESTION1

(Post hoc analysis. Results are descriptive. Definitive conclusions cannot be made.)1,a,b

a LSM difference between DUPIXENT 300 mg Q2W + INCS (n=438) and placebo + INCS (n=286): -0.07 (95% CI: -0.13, -0.01).1,2

Sustained improvement
in NC score through
Week 523,b,c
SINUS-52

bWeek 24 in SINUS-52 (coprimary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=295, pooled arms) and placebo + INCS (n=153): -0.87 (95% CI: -1.03, -0.71) (-1.25 from a baseline score of 2.46 vs -0.38 from a baseline score of 2.38, respectively) (P<0.0001).3,4

cWeek 52 in SINUS-52 (key secondary endpoint). LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.98 (95% CI: -1.17, -0.79) (-1.35 from a baseline score of 2.48 vs -0.37 from a baseline score of 2.38, respectively) (P<0.0001).3,4

dWeek 24 in SINUS-52. LSM difference between DUPIXENT 300 mg Q2W + INCS (n=150) and placebo + INCS (n=153): -0.79 (95% CI: -0.98, -0.61) (-1.17 from a baseline score of 2.48 vs -0.38 from a baseline score of 2.38, respectively).3

Nasal congestion/obstruction
(NC) score (range 0-3); reduced
score indicates improvement.4

INCS, intranasal corticosteroid;
LSM, least squares mean; Q2W,
once every 2 weeks.

Use of DUPIXENT for the CRSwNP
indication in patients aged 12-17
years is supported by evidence
from studies of DUPIXENT
as add-on maintenance
treatment
in adults with inadequately
controlled CRSwNP.4

SEE SINUS SURGERY + SCS USE DATA
Back to sense of smell

Explore the Safety Data
and Study Designs

VIEW safety data SEE THE FULL STUDY DESIGNS

Dosage and
Administration

See the recommended dosing and administration
options for patients
on DUPIXENT.

Explore ADMINISTRATION Options